ESC Premium Access

Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs)

Congress Presentation

About the speaker

Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)
5 presentations
0 follower

2 more presentations in this session

Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment

Speaker: Assistant Professor R. Badagliacca (Rome, IT)


Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil

Speaker: Doctor R. Sadushi-Kolici (Vienna, AT)


Access the full session

Advances in the Management of Pulmonary Arterial Hypertension

Speakers: Professor V. McLaughlin, Assistant Professor R. Badagliacca, Doctor R. Sadushi-Kolici

About the event


ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb